Evidence map›Paper›PMID 31334440›Full record

ArticleHepatology communications2019

Deficient IL-6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis.

Peter Stärkel, Bernd Schnabl, Sophie Leclercq, Mina Komuta, Ramon Bataller, Josepmaria Argemi, Elena Palma, Shilpa Chokshi, Claus Hellerbrand, Luca Maccioni and 2 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Best Practices and Progress in Precision-Cut Liver Slice Cultures.International journal of molecular sciences · 2021
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Peter StärkelDepartment of Hepato-gastroenterology Cliniques Universitaires Saint-Luc Brussels Belgium.
Bernd SchnablDepartment of Medicine University of California San Diego La Jolla CA.
Sophie LeclercqInstitute of Neuroscience Université Catholique de Louvain Brussels Belgium.
Mina KomutaDepartment of Pathology Cliniques Universitaires Saint-Luc Brussels Belgium.
Ramon BatallerDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine University of Pittsburgh Medical Center, Pittsburgh Liver Research Center Pittsburgh PA.
Josepmaria ArgemiDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine University of Pittsburgh Medical Center, Pittsburgh Liver Research Center Pittsburgh PA.
Elena PalmaInstitute of Hepatology Foundation for Liver Research London United Kingdom.
Shilpa ChokshiInstitute of Hepatology Foundation for Liver Research London United Kingdom.
Claus HellerbrandInstitute of Biochemistry Friedrich-Alexander University Erlangen-Nürnberg Erlangen Germany.
Luca MaccioniInstitute of Experimental and Clinical Research, Laboratory of Hepato-gastroenterology Université Catholique de Louvain Brussels Belgium.
Nicolas LanthierDepartment of Hepato-gastroenterology Cliniques Universitaires Saint-Luc Brussels Belgium.ORCID https://orcid.org/0000-0002-7651-9314
Isabelle LeclercqInstitute of Experimental and Clinical Research, Laboratory of Hepato-gastroenterology Université Catholique de Louvain Brussels Belgium.
Cliniques Universitaires Saint-Luc · BEUCLouvain · BEKing's College London · GBUniversity of Pittsburgh Medical Center · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity of California San Diego · US

Funding

The Role of the Intestinal Mycobiome in Alcoholic Liver DiseaseR01AA024726 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2018 to 2026
$3.9M
NIAAA NIH HHS R01 AA024726
6 · The paper itself

Abstract

Mechanisms underlying alcohol-induced liver injury and its progression still remain incompletely understood. Animal models can only address some aspects of the pathophysiology that requires studies directly in humans, which are scarce. We assessed liver inflammatory and immune responses at early stages of alcoholic liver disease in a unique cohort of alcohol-dependent patients undergoing a highly standardized alcohol withdrawal program. In active drinkers, quantitative real-time polymerase chain reaction revealed alcohol-induced activation of tumor necrosis factor alpha, interleukin (IL)-1β, and nuclear factor kappa B in liver tissue already at early disease stages. Double immunofluorescence staining indicated that this proinflammatory response was restricted to activated, CD68-positive macrophages. In parallel, down-regulation of IL-6, inhibition of the signal transducer and activator of transcription 3 (Stat3) pathway, as well as blunted cyclin D expression in hepatocytes, reduced proliferation and favored hepatocyte apoptosis. In addition, immunofluorescence and quantitative real-time polymerase chain reaction of liver tissue showed that alcohol also activated the toll-like receptor (TLR) 7-interferon (IFN) axis in hepatocytes, which was confirmed in alcohol-stimulated primary human hepatocytes and precision-cut liver slices

Identifiers

PMID31334440
PMCPMC6601428
OpenAlexW2944623642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.